University Of Southampton

Researchers from Lancaster University developed RI-AG03, a peptide inhibitor preventing Tau protein build-up in Alzheimer's disease. RI-AG03 targets both aggregation-promoting areas of Tau, potentially leading to more effective treatments. Lab studies and tests on genetically modified fruit flies showed significant suppression of neurodegeneration and extended lifespan. Human cell line tests also indicated reduced Tau fibril formation. The dual-targeting mechanism of RI-AG03 could offer safer treatment options compared to current therapies. Further research in rodents and clinical trials in humans are planned.

British researchers etched the human genome into a 5D memory crystal in an Austrian mountain, offering potential for long-term genetic preservation and restoration of extinct species.

Regular aspirin use may reduce pancreatic cancer risk by 40% in people with diabetes and by 20% in the general population, according to a UK study.

RI-AG03, a new peptide inhibitor, effectively targets both major aggregation-promoting hotspots of Tau proteins in lab and fruit fly studies, potentially improving Alzheimer’s treatment safety and efficacy.

A new drug, RI-AG03, targets two key regions of the tau protein, preventing its toxic build-up and showing promise in treating Alzheimer’s disease, as demonstrated in lab and fruit fly studies. Further research, including clinical trials, is necessary to validate its efficacy in humans.

Scientists developed RI-AG03, a peptide inhibitor targeting both major Tau protein hotspots, effective in preventing Tau build-up in lab and fruit fly studies. Dr. Aggidis, former Postdoctoral Research Associate at Lancaster University, believes this could lead to treatments for Alzheimer’s disease. The research, published in Alzheimer’s & Dementia, was a collaborative effort involving multiple institutions.

RI-AG03, a peptide inhibitor, effectively prevents Tau protein accumulation in Alzheimer's disease, targeting both key regions of the protein. Tested in fruit flies and biosensor cells, it extended life and reduced aggregation, with plans for rodent trials before clinical testing.

Scientists developed a drug, RI-AG03, targeting tau proteins to combat Alzheimer’s, showing efficacy in lab and fruit fly studies. The drug inhibits key regions affected by the disease, potentially offering more effective treatment with fewer side effects.

The iDx study targeted 3,400 participants, focusing on high-risk groups like dock workers and Afro-Caribbean communities. Mobile research units were used alongside NHS Lung Health Check vans for on-the-spot recruitment, overcoming barriers like travel and convenience. Agile Teams facilitated expansion to Portsmouth, enhancing recruitment potential and demonstrating the value of agile support in future research.

New UK-created cancer therapies to be trialled, benefiting NHS patients through partnerships with pharmaceutical companies and universities. Innovations include AI for early cancer detection and flexible medical scanners, aiming to transform treatment and boost the UK's life sciences industry.